These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36154786)

  • 1. Genetics of Pancreatic Neuroendocrine Tumors.
    Mohindroo C; McAllister F; De Jesus-Acosta A
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):1033-1051. PubMed ID: 36154786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Well-differentiated G1 and G2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded DNA sequencing data.
    Andersen KØ; Detlefsen S; Brusgaard K; Christesen HT
    Front Endocrinol (Lausanne); 2024; 15():1351624. PubMed ID: 38868744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.
    Chou WC; Lin PH; Yeh YC; Shyr YM; Fang WL; Wang SE; Liu CY; Chang PM; Chen MH; Hung YP; Li CP; Chao Y; Chen MH
    Int J Biol Sci; 2016; 12(12):1523-1532. PubMed ID: 27994516
    [No Abstract]   [Full Text] [Related]  

  • 4. Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification.
    Ishida H; Lam AK
    Crit Rev Oncol Hematol; 2022 Apr; 172():103648. PubMed ID: 35248713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple Endocrine Neoplasia Type 1 Syndrome Pancreatic Neuroendocrine Tumor Genotype/Phenotype: Is There Any Advance on Predicting or Preventing?
    Ramamoorthy B; Nilubol N
    Surg Oncol Clin N Am; 2023 Apr; 32(2):315-325. PubMed ID: 36925188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
    Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
    Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1.
    Marini F; Giusti F; Tonelli F; Brandi ML
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.
    Capurso G; Archibugi L; Delle Fave G
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):594-601. PubMed ID: 25619712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The genetics of neuroendocrine tumors.
    Öberg K
    Semin Oncol; 2013 Feb; 40(1):37-44. PubMed ID: 23391111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
    Maxwell JE; Sherman SK; Howe JR
    Clin Cancer Res; 2016 Oct; 22(20):5022-5029. PubMed ID: 27742788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations.
    Soczomski P; Jurecka-Lubieniecka B; Krzywon A; Cortez AJ; Zgliczynski S; Rogozik N; Oczko-Wojciechowska M; Pawlaczek A; Bednarczuk T; Jarzab B
    Front Endocrinol (Lausanne); 2021; 12():681013. PubMed ID: 34122352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current understanding of the molecular biology of pancreatic neuroendocrine tumors.
    Zhang J; Francois R; Iyer R; Seshadri M; Zajac-Kaye M; Hochwald SN
    J Natl Cancer Inst; 2013 Jul; 105(14):1005-17. PubMed ID: 23840053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
    Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
    Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.
    Nuñez JE; Donadio M; Filho DR; Rego JF; Barros M; Formiga MN; Lopez R; Riechelmann R
    J Gastrointest Oncol; 2019 Aug; 10(4):645-651. PubMed ID: 31392045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.
    Weisbrod AB; Zhang L; Jain M; Barak S; Quezado MM; Kebebew E
    Horm Cancer; 2013 Jun; 4(3):165-75. PubMed ID: 23361940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic neuroendocrine tumor in a patient with a TSC1 variant: case report and review of the literature.
    Mortaji P; Morris KT; Samedi V; Eberhardt S; Ryan S
    Fam Cancer; 2018 Apr; 17(2):275-280. PubMed ID: 28887784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.
    Wong HL; Yang KC; Shen Y; Zhao EY; Loree JM; Kennecke HF; Kalloger SE; Karasinska JM; Lim HJ; Mungall AJ; Feng X; Davies JM; Schrader K; Zhou C; Karsan A; Jones SJM; Laskin J; Marra MA; Schaeffer DF; Gorski SM; Renouf DJ
    Cold Spring Harb Mol Case Stud; 2018 Feb; 4(1):. PubMed ID: 29092957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convergence between germline and somatic mutations in pancreatic neuroendocrine tumors.
    Ling C; Hong X; Xu M; Wang Y; Ma X; Cui Y; Jiang R; Cao D; Wu H; Tong A; Zhao Y; Wu W
    Eur J Endocrinol; 2022 May; 187(1):85-90. PubMed ID: 35521758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms.
    Vandamme T; Beyens M; Boons G; Schepers A; Kamp K; Biermann K; Pauwels P; De Herder WW; Hofland LJ; Peeters M; Van Camp G; Op de Beeck K
    Endocr Relat Cancer; 2019 Jan; 26(1):1-12. PubMed ID: 30021865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.